Pharmaceutical composition for inhibition of ras proto-oncogene overexpression

Abstract

The invention relates to an application of a pharmaceutical composition in inhibition of ras proto-oncogene overexpression, and specifically, relates to the application in preparation of anti-tumor drugs for inhibiting ras proto-oncogene overexpression. Specifically, the pharmaceutical composition contains radix ginseng, radix ophiopogonis and schisandra chinensis fruits. Researches indicate that about 90% of pancreatic cancer, 50% of colon cancer, 30%-40% of lung adenocarcinoma and 5%-40% of leukemia are caused by the ras proto-oncogene overexpression, and a Ras protein becomes a universally accepted target for screening related malignant tumor drugs. Animal experiments indicate that the pharmaceutical composition can specifically down-regulate overexpression caused after ras proto-oncogene mutation, but does not act on wild-type ras proto-oncogenes, so that the pharmaceutical composition is low in toxicity and has no teratogenic effect and no reproduction toxicity; the pharmaceutical composition can be used for preparation of drugs for tumors caused by overexpression after ras proto-oncogene mutation, can be mixed with any one of pharmaceutically acceptable auxiliary materials to prepare various dosage forms, and is expected to be developed into a new-generation antitumor drugs.

Description

technical field [0001] The present invention relates to the application of a pharmaceutical composition in inhibiting the overexpression of the ras proto-oncogene, in particular to the application in the preparation of tumor drugs caused by the overexpression of the ras proto-oncogene after mutation, specifically the composition contains ginseng , Ophiopogon japonicus and Schisandra chinensis belong to the field of antineoplastic drugs. Background technique [0002] At present, malignant tumors have become the number one killer of human beings, seriously endangering human health. According to the data of the World Health Organization, the incidence of tumors in the world is 10 million people every year, and about 7 million people die. The number of cases is 2 million, and the death due to cancer is about 1.4 million. Among the 5 people who die in our country, 1 person dies from cancer. [0003] About 30% of human tumors are caused by the activation of Ras proto-oncogene aft...

AI Technical Summary

Problems solved by technology

On December 20, 2005, Nexavar, a drug for the treatment of advanced renal cell carcinoma approved by the US FDA, directly targets the Ras signaling pathway, which can inhibit the Raf / MEK / ERK signaling pathway and directly inhibit tumor growth; Kinase inhibitors such as ID1839 and OSI774, which can effectively block the activity of EGFR tyrosine kinase and also inhibit other members of the ERBB protein family to some extent, but these are not drugs directly targeting ras, with Ras protein as the main Target farnesylation transferase inhibitors can also inhibit the farnesylation of most other proteins (maybe including some normal human proteins), with poor specificity. Therefore, it is necessary to develop safe and efficient anti-tumor drugs for the treatment of excessive activation of ras proto-oncogenes Medication is a priority

[0009] So far, no literature has reported that the composition containing ginseng, Ophiopogon japonicus, and Schisandra can inhibit the overexpression of the ras proto-oncogene after mutation, and there is no such composition containing Composition of ginseng, Ophiopogon japonicus, and schisandra as raw materials can specifically inhibit the tumor caused by the overexpression of ras proto-oncogene mutation

Images